SCHEMBL349820

SCHEMBL349820

NC(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.60
TPMT P51580 1/20 0.59
TSHR P16473 2/20 0.44
HCAR1 Q9BXC0 1/20 0.44
ADRA1D P25100 1/20 0.44
CYP3A4 P08684 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAP4K4 O95819 2/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4371939 0.97 PARP1 (0.58) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL14060424 0.95 PARP1 (0.56) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL5048829 0.94 PARP1 (0.60) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL28037673 0.87 PARP1 (0.48) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL4339312 0.85 HCAR1 (0.65) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL16952186 0.84 PARP1 (0.50) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL1363329 0.84 PARP1 (0.50) PARP1TPMTTSHRHCAR1ADRA1D
SCHEMBL9631667 0.84 PARP1 (0.50) PARP1TPMTHCAR1ADRA1DCYP3A4
SCHEMBL22383502 0.84 PARP1 (0.50) PARP1TPMTHCAR1ADRA1DMAP4K4
SCHEMBL30463182 0.84 PARP1 (0.50) PARP1TPMTHCAR1ADRA1DCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119875232-A Flame-retardant cable and preparation method thereof 佰汇电缆有限公司 2025-04-25 CN claimed
CN-113372290-A Synthetic method of drug Tafamidis 遵义医科大学 2021-09-10 CN claimed
CN-109232649-B Tetrazole urease inhibitor type feed additive and preparation method thereof 北京绿摇饲料科技有限公司 2020-08-25 CN claimed
CN-109232646-B Triazole urease inhibitor type feed additive and preparation method thereof 赣州澳德饲料科技有限公司 2020-08-21 CN claimed
CN-110642741-A Functionalized benzamide derivatives as antiviral agents against HBV infection 巴鲁克斯布隆伯格研究所 2020-01-03 CN claimed
CN-104918612-B Functionalized benzamide derivatives as antiviral agents against HBV infection 巴鲁克斯布隆伯格研究所 2019-10-25 CN claimed
CN-109232646-A A kind of triazole urease inhibitor type feed addictive and preparation method thereof 河南湾流生物科技有限公司 2019-01-18 CN claimed
CN-109232649-A A kind of tetrazole urease inhibitor type feed addictive and preparation method thereof 河南湾流生物科技有限公司 2019-01-18 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
CN-105542584-A Thermal-inductive fluorocarbon function coating containing azobenzene/carbon-hybrid material and preparation method of thermal-inductive fluorocarbon function coating UNIV TIANJIN 2016-05-04 CN claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 WO claimed
WO-2003059899-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-07-24 WO claimed
US-20030069259-A1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents AVENTISUB LLC 2003-04-10 US claimed
WO-2002044126-A2 BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS GUILFORD PHARMACEUTICALS INC. (US) 2002-06-06 WO claimed
WO-2002042303-A2 ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS AVENTIS PHARMACEUTICALS INC. (US) 2002-05-30 WO claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
CN-1246112-A Improved process for preparation of halo-4-phenoxyquinolines DOW AGROSCIENCES LLC (US) 2000-03-01 CN claimed
WO-1993014062-A1 ANTHELMINTIC β-KETOAMIDES THE UPJOHN COMPANY (US) 1993-07-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069259-A1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents BAD, BAX, MCL1 PARP1 208/4885TPMT 321/4885TSHR 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.